Raymond James Financial’s Cardiff Oncology CRDF Stock Holding History

Raymond James Financial’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.5K	Hold	22,672	–	–	﹤0.01%	5308
2026 Q1	$36.7K	Sell	22,672 -4,000	-15%	-$8.21K	﹤0.01%	5152
2025 Q4	$74.9K	Buy	26,672 +3,040	+13%	+$7.06K	﹤0.01%	4969
2025 Q3	$48.7K	Buy	23,632 +9,740	+70%	+$26.9K	﹤0.01%	4829
2025 Q2	$43.8K	Buy	13,892 +1,417	+11%	+$4.32K	﹤0.01%	5238
2025 Q1	$39.2K	Sell	12,475 -521	-4%	-$2.06K	﹤0.01%	4657
2024 Q4	$56.4K	Buy	+12,996	New	+$40.6K	﹤0.01%	4595

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Raymond James Financial's CRDF Position: Q2 2026 in Review

Raymond James Financial held its Cardiff Oncology (CRDF) position steady in Q2 2026 at 22,672 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5308.

Raymond James Financial first reported a position in CRDF in Q4 2024 and has held it in 7 quarters since. The position peaked at $74.9K in Q4 2025. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Raymond James Financial held 22,672 shares of Cardiff Oncology worth $29.5K as of Q2 2026.
Raymond James Financial left its Cardiff Oncology share count unchanged in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5308 holding.
Raymond James Financial first reported a position in Cardiff Oncology in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Cardiff Oncology position peaked at $74.9K in Q4 2025.
104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.